Symposium I – Bone & Mineral Metabolism Disorders
Achondroplasia and Hypochondroplasia Management including Evolving Therapies
After this presentation, you will be able to:
- Describe clinical characteristics of achondroplasia and hypochondroplasia and how to differentiate between them
- Review the role of Fibroblast Growth Factor Receptor 3 (FGFR3) gene as a “negative regulator” of bone growth
- Assess benefits and limitations of novel growth-modulating therapies, specifically vosoritide (C-type natriuretic peptide analogue) in mitigating long-term complications and improving linear growth
Bone Mineral Metabolism Phosphate Wasting
After this presentation, you will be able to:
- Identify the molecular mechanisms of renal phosphate handling
- Map the pathophysiology of FGF23-Mediated Disorders
- Differentiate between genetic and acquired causes of hypophosphatemic rickets
Symposium II – Endocrine Late Effects of Cancer Therapy
Endocrine Late Effects of Cancer-Related Therapy
After this presentation, you will be able to:
- Identify the spectrum and prevalence of endocrine late effects in childhood cancer survivors
- Recognize treatment-specific risk factors and dose-response relationships for endocrine toxicity
- Apply evidence-based surveillance strategies for early detection and management of endocrine complications
Oral Abstracts I and II
After these presentations, you will be able to:
- Describe recent research activity in the field of Pediatric Endocrinology and Diabetes within Canada
- Apply key insights from recent research into their own education/clinical/research practices
Symposium III – Congenital Hyperinsulinism (CHI)
Update on Genetics of Congenital Hyperinsulinism & Imaging and Surgical Outcomes in Congenital Hyperinsulinism
After these presentations, you will be able to:
- Evaluate current medical management options including diazoxide and somatostatin analogues
- Differentiate between focal, diffuse, and atypical forms of CHI using [18F]-DOPA PET/CT imaging to guide surgical planning
- Examine emerging pharmacological therapies such as novel glucagon analogues and monoclonal antibodies targeting insulin receptors
Symposium IV – Diabetes
Stem Cell Transplantation
After this presentation, you will be able to:
- Understand the evolution from cadaveric islet transplantation to stem cell-derived beta cell therapy
- Recognize the key challenges limiting widespread clinical adoption and strategies to overcome them
- Evaluate current clinical outcomes and future directions for cell replacement therapy in diabetes
Universal Screening/Intervention in T1DM
After this presentation, you will be able to:
- Describe the natural history of islet autoantibodies in the progression of type 1 DM
- Recognize the historical successes, present-day challenges, and future implications in standardizing lab assays to detect and quantify islet autoantibodies
- Assess the benefits and limitations of measuring and monitoring islet autoantibodies in clinical decision-making
Debate
Should Sensor-Augmented Insulin Pump therapy be started at diagnosis of type 1 diabetes mellitus (T1DM)?
After this presentation, you will be able to:
- Understand current guidelines for use of technology in the management of T1DM at diagnosis
- Review the advantages and disadvantages of pump therapy at diagnosis of T1DM
- Consider different perspectives in caring for children with T1DM